AR127421A1 - Formulaciones farmacéuticas que comprenden anticuerpos anti-tg2. - Google Patents
Formulaciones farmacéuticas que comprenden anticuerpos anti-tg2.Info
- Publication number
- AR127421A1 AR127421A1 ARP220102861A ARP220102861A AR127421A1 AR 127421 A1 AR127421 A1 AR 127421A1 AR P220102861 A ARP220102861 A AR P220102861A AR P220102861 A ARP220102861 A AR P220102861A AR 127421 A1 AR127421 A1 AR 127421A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical formulations
- antibodies
- liquid pharmaceutical
- relates
- tampon
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invención se refiere al campo de las formulaciones farmacéuticas. Más particularmente, se refiere a formulaciones farmacéuticas líquidas que comprenden anticuerpos anti-TG2 y a métodos para producir tales formulaciones farmacéuticas. Las formulaciones farmacéuticas líquidas según la invención son estables tras el almacenamiento a una temperatura de aproximadamente 2ºC a 25ºC durante un periodo adecuado. Reivindicación 1: Una composición farmacéutica líquida caracterizada por: a) un anticuerpo anti-TG2; b) un tampón; c) un estabilizador seleccionado del grupo que consiste en glicina o NaCl; y d) un pH entre 5,0 y 7,0.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2115121.2A GB202115121D0 (en) | 2021-10-21 | 2021-10-21 | Formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127421A1 true AR127421A1 (es) | 2024-01-24 |
Family
ID=78806158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102861A AR127421A1 (es) | 2021-10-21 | 2022-10-20 | Formulaciones farmacéuticas que comprenden anticuerpos anti-tg2. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240415769A1 (es) |
| EP (1) | EP4419078A1 (es) |
| JP (1) | JP2024539265A (es) |
| KR (1) | KR20240099311A (es) |
| CN (1) | CN118119377A (es) |
| AR (1) | AR127421A1 (es) |
| AU (1) | AU2022372646A1 (es) |
| CA (1) | CA3235381A1 (es) |
| CL (1) | CL2024001229A1 (es) |
| CO (1) | CO2024006193A2 (es) |
| GB (1) | GB202115121D0 (es) |
| GE (2) | GEP20257800B (es) |
| IL (1) | IL312207A (es) |
| MX (1) | MX2024004872A (es) |
| PE (1) | PE20241193A1 (es) |
| TW (1) | TW202323288A (es) |
| WO (1) | WO2023067049A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006100679A2 (en) | 2005-03-22 | 2006-09-28 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against human type ii transglutaminase and uses thereof |
| GB2490655A (en) | 2011-04-28 | 2012-11-14 | Univ Aston | Modulators of tissue transglutaminase |
| GB201209096D0 (en) | 2012-05-24 | 2012-07-04 | Medical Res Council Technology | Compounds |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| MX2018009341A (es) * | 2016-02-03 | 2019-05-15 | Oncobiologics Inc | Formulaciones tamponadas para una mayor estabilidad de anticuerpos. |
-
2021
- 2021-10-21 GB GBGB2115121.2A patent/GB202115121D0/en not_active Ceased
-
2022
- 2022-10-20 CA CA3235381A patent/CA3235381A1/en active Pending
- 2022-10-20 IL IL312207A patent/IL312207A/en unknown
- 2022-10-20 AU AU2022372646A patent/AU2022372646A1/en active Pending
- 2022-10-20 US US18/703,661 patent/US20240415769A1/en active Pending
- 2022-10-20 AR ARP220102861A patent/AR127421A1/es unknown
- 2022-10-20 JP JP2024524494A patent/JP2024539265A/ja active Pending
- 2022-10-20 WO PCT/EP2022/079182 patent/WO2023067049A1/en not_active Ceased
- 2022-10-20 KR KR1020247016530A patent/KR20240099311A/ko active Pending
- 2022-10-20 EP EP22817522.0A patent/EP4419078A1/en active Pending
- 2022-10-20 CN CN202280070135.8A patent/CN118119377A/zh active Pending
- 2022-10-20 GE GEAP202216520A patent/GEP20257800B/en unknown
- 2022-10-20 GE GEAP202416520A patent/GEAP202416520A/en unknown
- 2022-10-20 PE PE2024000910A patent/PE20241193A1/es unknown
- 2022-10-20 MX MX2024004872A patent/MX2024004872A/es unknown
- 2022-10-20 TW TW111139753A patent/TW202323288A/zh unknown
-
2024
- 2024-04-19 CL CL2024001229A patent/CL2024001229A1/es unknown
- 2024-05-16 CO CONC2024/0006193A patent/CO2024006193A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB202115121D0 (en) | 2021-12-08 |
| EP4419078A1 (en) | 2024-08-28 |
| WO2023067049A1 (en) | 2023-04-27 |
| GEAP202416520A (en) | 2024-07-25 |
| KR20240099311A (ko) | 2024-06-28 |
| AU2022372646A1 (en) | 2024-06-06 |
| IL312207A (en) | 2024-06-01 |
| CL2024001229A1 (es) | 2024-09-13 |
| CO2024006193A2 (es) | 2024-05-30 |
| CA3235381A1 (en) | 2023-04-27 |
| PE20241193A1 (es) | 2024-06-03 |
| JP2024539265A (ja) | 2024-10-28 |
| CN118119377A (zh) | 2024-05-31 |
| MX2024004872A (es) | 2024-05-06 |
| TW202323288A (zh) | 2023-06-16 |
| US20240415769A1 (en) | 2024-12-19 |
| GEP20257800B (en) | 2025-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
| CL2019003049A1 (es) | Compuestos de heteroarilo bicíclicos 6-6 fusionados y su uso como inhibidores de lats. | |
| CL2021000517A1 (es) | Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003) | |
| EA201991701A1 (ru) | Состав на основе моноклонального антитела к rsv | |
| CR20200452A (es) | Compuestos de aminoacidos y métodos de uso | |
| CO2019011021A2 (es) | Formulacion estable de anticuerpos | |
| CL2021002241A1 (es) | Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570) | |
| MX2019010282A (es) | Formulacion de anticuerpos monoclonales. | |
| JP2017222654A5 (es) | ||
| MX2023005994A (es) | Composiciones de inhibidores peptidicos del receptor de interleucina-23. | |
| BR112017016434A2 (pt) | ?cristal de um anticorpo monoclonal anti-pd-1, métodos para produzir cristais de um anticorpo monoclonal anti-pd-1, para cristalizar um anticorpo monoclonal anti-pd-1 e para tratamento de um indivíduo humano, e, composição farmacêutica? | |
| AR053608A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos | |
| EA201991769A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ С НИЗКИМ ПОКАЗАТЕЛЕМ pH, СОДЕРЖАЩАЯ КОНСТРУКЦИИ НА ОСНОВЕ АНТИТЕЛА, ОСУЩЕСТВЛЯЮЩИЕ РЕКРУТИНГ Т-КЛЕТОК | |
| BRPI0406715A (pt) | Inibidores seletivos de ciclooxigenase-2 antiinflamatórios | |
| CL2018000622A1 (es) | Acetamida tienodiazepinas de triazol y sus usos relacionados. | |
| AR035539A1 (es) | Moleculas de enlace capaces de enlazarse a isoformas cd45, polinucleotidos codificantes, un vector de expresion, un sistema de expresion, una celula huesped, el uso de dichas moleculas para la produccion de un medicamento y composiciones farmaceuticas. | |
| CL2021003568A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina (divisional de solicitud n° 202101198) | |
| CL2024002767A1 (es) | Moduladores de nlrp3 | |
| CL2021002440A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-il-33. | |
| CO2022005737A2 (es) | Formulación estable de anticuerpo de integrina | |
| AR127421A1 (es) | Formulaciones farmacéuticas que comprenden anticuerpos anti-tg2. | |
| MX2021008071A (es) | Derivados de imidazol fusionado sustituido y métodos de tratamiento de la anemia de células falciformes y complicaciones relacionadas. | |
| GT200600421A (es) | Formas cristalinas polimórficas de la sal de di-sodio del ácido n-(5-clorosaliciloil)-8-aminocaprilico | |
| UY40050A (es) | Formulaciones para anticuerpos pegilados | |
| MX2024006091A (es) | Metodo para el tratamiento de una enfermedad de esclerodermia. |